Cangzhou Central Hospital

Cangzhou, Hebei 61011

3 studies enrolling now · 5 studies all time

What they study most

Acute Myocardial Infarction (AMI), Acute Non-cardioembolic Ischemic Stroke, Atrial Fibrillation, Cardiovascular Risk, High-risk Transient Ischemic Attack, Immunoglobulin A Nephropathy (IgAN), Melanoma, Non-small Cell Lung Cancer, Prevention of Ischemic Stroke, Prevention of Stroke or Systemic Embolism, Renal Cell Carcinoma

Studies at this site

• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) — Recruiting now
• A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors — Recruiting now
• ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack — Recruiting now
• A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke — Completed
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early